Estimation of Anti-SARS-CoV-2 IgM/IgG Seroprevalence Among Non-Vaccinated and Vaccinated University Students: A Cross-Sectional Egyptian Study
It is essential to comprehend the humoral immune response to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its vaccines to maximize the effectiveness of anti-SARSCoV-2 community immunization efforts. The aim of this cross-sectional study was to determine the seroprevalence of anti...
Saved in:
Published in | Viruses Vol. 17; no. 3; p. 378 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
MDPI AG
06.03.2025
MDPI |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | It is essential to comprehend the humoral immune response to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its vaccines to maximize the effectiveness of anti-SARSCoV-2 community immunization efforts. The aim of this cross-sectional study was to determine the seroprevalence of anti-SARS-CoV-2 IgM/IgG among newcomer students at Kafr Elsheikh University in Egypt, whether they had been vaccinated or not. Blood samples from 400 healthy newcomer students (200 non-vaccinated and 200 vaccinated) were evaluated for the presence of anti-SARS-CoV-2 IgM/IgG using colloidal gold immunochromatography lateral flow immunoassay cards, and then the results were confirmed by using specific ELISA tests. The prevalence of anti-SARS-CoV-2 antibodies among the participants (n = 400) was 56.3% for IgG and 13.3% for IgM. Regarding the non-vaccinated participants, 55.0% were females, the mean age was 18.2 years, and the mean BMI was 25.35. Regarding the vaccinated participants, 58.5% were females, the mean age was 18.1 years, and the mean BMI was 25.3. There were statistically non-significant correlations (p ˃ 0.05) between gender, BMI, and each of IgM- or IgG-positivity in both vaccinated and non-vaccinated groups. In total, 41.5% and 48.5% of the anti-SARS-CoV-2 IgM-positive and anti-SARS-CoV-2 IgG-positive participants were non-vaccinated, respectively. Furthermore, 58.5% and 51.5% of the anti-SARS-CoV-2 IgM-positive and anti-SARS-CoV-2 IgG-positive participants were vaccinated, respectively. No statistically significant association (p ˃ 0.05) in immunoglobulins positivity between the anti-SARS-CoV-2 non-vaccinated, and vaccinated groups. The anti-SARS-CoV-2 immunological response of nonsmokers, people who exercise regularly, and those who take vitamin supplements, eat a balanced diet, and use certain herbs is noteworthy. Among the vaccinated subjects, 96.6%, 25.0%, 31.9%, 45.7%, and 7.8% of the IgG-positive group, versus 97.2%, 60.6%, 64.2%, 52.3%, and 6.4% of the IgG-positive non-vaccinated group, were nonsmokers, exercisers, and those taking vitamin supplements, eating a balanced diet, and using herbs, respectively. Furthermore, 93.5%, 32.3%, 35.5%, 48.4%, and 6.5% of the IgM-positive vaccinated group, versus 100.0%, 63.6%, 81.8%, 45.5%, and 4.5% of the IgM-positive non-vaccinated participants, were nonsmokers, physical exercisers, vitamin supplement users, balanced eaters, and herbalists, respectively. Persons who are free from comorbidities, young, non-obese, non-smokers, engage in physical exercise, take vitamins, eat a balanced diet, and use certain immunostimulant herbal supplements, all have a strong anti-SARS-CoV-2 humoral immune response, even if they were not vaccinated. During pandemics, vaccination of this group should not be a priority to preserve vaccine doses for high-risk vulnerable people. Even if there is a lockdown during an anticipated future epidemic or pandemic, we should prioritize healthy eating and lifestyle choices, along with increasing physical activity. |
---|---|
AbstractList | It is essential to comprehend the humoral immune response to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its vaccines to maximize the effectiveness of anti-SARSCoV-2 community immunization efforts. The aim of this cross-sectional study was to determine the seroprevalence of anti-SARS-CoV-2 IgM/IgG among newcomer students at Kafr Elsheikh University in Egypt, whether they had been vaccinated or not. Blood samples from 400 healthy newcomer students (200 non-vaccinated and 200 vaccinated) were evaluated for the presence of anti-SARS-CoV-2 IgM/IgG using colloidal gold immunochromatography lateral flow immunoassay cards, and then the results were confirmed by using specific ELISA tests. The prevalence of anti-SARS-CoV-2 antibodies among the participants (n = 400) was 56.3% for IgG and 13.3% for IgM. Regarding the non-vaccinated participants, 55.0% were females, the mean age was 18.2 years, and the mean BMI was 25.35. Regarding the vaccinated participants, 58.5% were females, the mean age was 18.1 years, and the mean BMI was 25.3. There were statistically non-significant correlations (p ˃ 0.05) between gender, BMI, and each of IgM- or IgG-positivity in both vaccinated and non-vaccinated groups. In total, 41.5% and 48.5% of the anti-SARS-CoV-2 IgM-positive and anti-SARS-CoV-2 IgG-positive participants were non-vaccinated, respectively. Furthermore, 58.5% and 51.5% of the anti-SARS-CoV-2 IgM-positive and anti-SARS-CoV-2 IgG-positive participants were vaccinated, respectively. No statistically significant association (p ˃ 0.05) in immunoglobulins positivity between the anti-SARS-CoV-2 non-vaccinated, and vaccinated groups. The anti-SARS-CoV-2 immunological response of nonsmokers, people who exercise regularly, and those who take vitamin supplements, eat a balanced diet, and use certain herbs is noteworthy. Among the vaccinated subjects, 96.6%, 25.0%, 31.9%, 45.7%, and 7.8% of the IgG-positive group, versus 97.2%, 60.6%, 64.2%, 52.3%, and 6.4% of the IgG-positive non-vaccinated group, were nonsmokers, exercisers, and those taking vitamin supplements, eating a balanced diet, and using herbs, respectively. Furthermore, 93.5%, 32.3%, 35.5%, 48.4%, and 6.5% of the IgM-positive vaccinated group, versus 100.0%, 63.6%, 81.8%, 45.5%, and 4.5% of the IgM-positive non-vaccinated participants, were nonsmokers, physical exercisers, vitamin supplement users, balanced eaters, and herbalists, respectively. Persons who are free from comorbidities, young, non-obese, non-smokers, engage in physical exercise, take vitamins, eat a balanced diet, and use certain immunostimulant herbal supplements, all have a strong anti-SARS-CoV-2 humoral immune response, even if they were not vaccinated. During pandemics, vaccination of this group should not be a priority to preserve vaccine doses for high-risk vulnerable people. Even if there is a lockdown during an anticipated future epidemic or pandemic, we should prioritize healthy eating and lifestyle choices, along with increasing physical activity.It is essential to comprehend the humoral immune response to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its vaccines to maximize the effectiveness of anti-SARSCoV-2 community immunization efforts. The aim of this cross-sectional study was to determine the seroprevalence of anti-SARS-CoV-2 IgM/IgG among newcomer students at Kafr Elsheikh University in Egypt, whether they had been vaccinated or not. Blood samples from 400 healthy newcomer students (200 non-vaccinated and 200 vaccinated) were evaluated for the presence of anti-SARS-CoV-2 IgM/IgG using colloidal gold immunochromatography lateral flow immunoassay cards, and then the results were confirmed by using specific ELISA tests. The prevalence of anti-SARS-CoV-2 antibodies among the participants (n = 400) was 56.3% for IgG and 13.3% for IgM. Regarding the non-vaccinated participants, 55.0% were females, the mean age was 18.2 years, and the mean BMI was 25.35. Regarding the vaccinated participants, 58.5% were females, the mean age was 18.1 years, and the mean BMI was 25.3. There were statistically non-significant correlations (p ˃ 0.05) between gender, BMI, and each of IgM- or IgG-positivity in both vaccinated and non-vaccinated groups. In total, 41.5% and 48.5% of the anti-SARS-CoV-2 IgM-positive and anti-SARS-CoV-2 IgG-positive participants were non-vaccinated, respectively. Furthermore, 58.5% and 51.5% of the anti-SARS-CoV-2 IgM-positive and anti-SARS-CoV-2 IgG-positive participants were vaccinated, respectively. No statistically significant association (p ˃ 0.05) in immunoglobulins positivity between the anti-SARS-CoV-2 non-vaccinated, and vaccinated groups. The anti-SARS-CoV-2 immunological response of nonsmokers, people who exercise regularly, and those who take vitamin supplements, eat a balanced diet, and use certain herbs is noteworthy. Among the vaccinated subjects, 96.6%, 25.0%, 31.9%, 45.7%, and 7.8% of the IgG-positive group, versus 97.2%, 60.6%, 64.2%, 52.3%, and 6.4% of the IgG-positive non-vaccinated group, were nonsmokers, exercisers, and those taking vitamin supplements, eating a balanced diet, and using herbs, respectively. Furthermore, 93.5%, 32.3%, 35.5%, 48.4%, and 6.5% of the IgM-positive vaccinated group, versus 100.0%, 63.6%, 81.8%, 45.5%, and 4.5% of the IgM-positive non-vaccinated participants, were nonsmokers, physical exercisers, vitamin supplement users, balanced eaters, and herbalists, respectively. Persons who are free from comorbidities, young, non-obese, non-smokers, engage in physical exercise, take vitamins, eat a balanced diet, and use certain immunostimulant herbal supplements, all have a strong anti-SARS-CoV-2 humoral immune response, even if they were not vaccinated. During pandemics, vaccination of this group should not be a priority to preserve vaccine doses for high-risk vulnerable people. Even if there is a lockdown during an anticipated future epidemic or pandemic, we should prioritize healthy eating and lifestyle choices, along with increasing physical activity. It is essential to comprehend the humoral immune response to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its vaccines to maximize the effectiveness of anti-SARSCoV-2 community immunization efforts. The aim of this cross-sectional study was to determine the seroprevalence of anti-SARS-CoV-2 IgM/IgG among newcomer students at Kafr Elsheikh University in Egypt, whether they had been vaccinated or not. Blood samples from 400 healthy newcomer students (200 non-vaccinated and 200 vaccinated) were evaluated for the presence of anti-SARS-CoV-2 IgM/IgG using colloidal gold immunochromatography lateral flow immunoassay cards, and then the results were confirmed by using specific ELISA tests. The prevalence of anti-SARS-CoV-2 antibodies among the participants ( n = 400) was 56.3% for IgG and 13.3% for IgM. Regarding the non-vaccinated participants, 55.0% were females, the mean age was 18.2 years, and the mean BMI was 25.35. Regarding the vaccinated participants, 58.5% were females, the mean age was 18.1 years, and the mean BMI was 25.3. There were statistically non-significant correlations ( p ˃ 0.05) between gender, BMI, and each of IgM- or IgG-positivity in both vaccinated and non-vaccinated groups. In total, 41.5% and 48.5% of the anti-SARS-CoV-2 IgM-positive and anti-SARS-CoV-2 IgG-positive participants were non-vaccinated, respectively. Furthermore, 58.5% and 51.5% of the anti-SARS-CoV-2 IgM-positive and anti-SARS-CoV-2 IgG-positive participants were vaccinated, respectively. No statistically significant association ( p ˃ 0.05) in immunoglobulins positivity between the anti-SARS-CoV-2 non-vaccinated, and vaccinated groups. The anti-SARS-CoV-2 immunological response of nonsmokers, people who exercise regularly, and those who take vitamin supplements, eat a balanced diet, and use certain herbs is noteworthy. Among the vaccinated subjects, 96.6%, 25.0%, 31.9%, 45.7%, and 7.8% of the IgG-positive group, versus 97.2%, 60.6%, 64.2%, 52.3%, and 6.4% of the IgG-positive non-vaccinated group, were nonsmokers, exercisers, and those taking vitamin supplements, eating a balanced diet, and using herbs, respectively. Furthermore, 93.5%, 32.3%, 35.5%, 48.4%, and 6.5% of the IgM-positive vaccinated group, versus 100.0%, 63.6%, 81.8%, 45.5%, and 4.5% of the IgM-positive non-vaccinated participants, were nonsmokers, physical exercisers, vitamin supplement users, balanced eaters, and herbalists, respectively. Persons who are free from comorbidities, young, non-obese, non-smokers, engage in physical exercise, take vitamins, eat a balanced diet, and use certain immunostimulant herbal supplements, all have a strong anti-SARS-CoV-2 humoral immune response, even if they were not vaccinated. During pandemics, vaccination of this group should not be a priority to preserve vaccine doses for high-risk vulnerable people. Even if there is a lockdown during an anticipated future epidemic or pandemic, we should prioritize healthy eating and lifestyle choices, along with increasing physical activity. It is essential to comprehend the humoral immune response to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its vaccines to maximize the effectiveness of anti-SARSCoV-2 community immunization efforts. The aim of this cross-sectional study was to determine the seroprevalence of anti-SARS-CoV-2 IgM/IgG among newcomer students at Kafr Elsheikh University in Egypt, whether they had been vaccinated or not. Blood samples from 400 healthy newcomer students (200 non-vaccinated and 200 vaccinated) were evaluated for the presence of anti-SARS-CoV-2 IgM/IgG using colloidal gold immunochromatography lateral flow immunoassay cards, and then the results were confirmed by using specific ELISA tests. The prevalence of anti-SARS-CoV-2 antibodies among the participants ( = 400) was 56.3% for IgG and 13.3% for IgM. Regarding the non-vaccinated participants, 55.0% were females, the mean age was 18.2 years, and the mean BMI was 25.35. Regarding the vaccinated participants, 58.5% were females, the mean age was 18.1 years, and the mean BMI was 25.3. There were statistically non-significant correlations ( ˃ 0.05) between gender, BMI, and each of IgM- or IgG-positivity in both vaccinated and non-vaccinated groups. In total, 41.5% and 48.5% of the anti-SARS-CoV-2 IgM-positive and anti-SARS-CoV-2 IgG-positive participants were non-vaccinated, respectively. Furthermore, 58.5% and 51.5% of the anti-SARS-CoV-2 IgM-positive and anti-SARS-CoV-2 IgG-positive participants were vaccinated, respectively. No statistically significant association ( ˃ 0.05) in immunoglobulins positivity between the anti-SARS-CoV-2 non-vaccinated, and vaccinated groups. The anti-SARS-CoV-2 immunological response of nonsmokers, people who exercise regularly, and those who take vitamin supplements, eat a balanced diet, and use certain herbs is noteworthy. Among the vaccinated subjects, 96.6%, 25.0%, 31.9%, 45.7%, and 7.8% of the IgG-positive group, versus 97.2%, 60.6%, 64.2%, 52.3%, and 6.4% of the IgG-positive non-vaccinated group, were nonsmokers, exercisers, and those taking vitamin supplements, eating a balanced diet, and using herbs, respectively. Furthermore, 93.5%, 32.3%, 35.5%, 48.4%, and 6.5% of the IgM-positive vaccinated group, versus 100.0%, 63.6%, 81.8%, 45.5%, and 4.5% of the IgM-positive non-vaccinated participants, were nonsmokers, physical exercisers, vitamin supplement users, balanced eaters, and herbalists, respectively. Persons who are free from comorbidities, young, non-obese, non-smokers, engage in physical exercise, take vitamins, eat a balanced diet, and use certain immunostimulant herbal supplements, all have a strong anti-SARS-CoV-2 humoral immune response, even if they were not vaccinated. During pandemics, vaccination of this group should not be a priority to preserve vaccine doses for high-risk vulnerable people. Even if there is a lockdown during an anticipated future epidemic or pandemic, we should prioritize healthy eating and lifestyle choices, along with increasing physical activity. It is essential to comprehend the humoral immune response to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its vaccines to maximize the effectiveness of anti-SARSCoV-2 community immunization efforts. The aim of this cross-sectional study was to determine the seroprevalence of anti-SARS-CoV-2 IgM/IgG among newcomer students at Kafr Elsheikh University in Egypt, whether they had been vaccinated or not. Blood samples from 400 healthy newcomer students (200 non-vaccinated and 200 vaccinated) were evaluated for the presence of anti-SARS-CoV-2 IgM/IgG using colloidal gold immunochromatography lateral flow immunoassay cards, and then the results were confirmed by using specific ELISA tests. The prevalence of anti-SARS-CoV-2 antibodies among the participants (n = 400) was 56.3% for IgG and 13.3% for IgM. Regarding the non-vaccinated participants, 55.0% were females, the mean age was 18.2 years, and the mean BMI was 25.35. Regarding the vaccinated participants, 58.5% were females, the mean age was 18.1 years, and the mean BMI was 25.3. There were statistically non-significant correlations (p ˃ 0.05) between gender, BMI, and each of IgM- or IgG-positivity in both vaccinated and non-vaccinated groups. In total, 41.5% and 48.5% of the anti-SARS-CoV-2 IgM-positive and anti-SARS-CoV-2 IgG-positive participants were non-vaccinated, respectively. Furthermore, 58.5% and 51.5% of the anti-SARS-CoV-2 IgM-positive and anti-SARS-CoV-2 IgG-positive participants were vaccinated, respectively. No statistically significant association (p ˃ 0.05) in immunoglobulins positivity between the anti-SARS-CoV-2 non-vaccinated, and vaccinated groups. The anti-SARS-CoV-2 immunological response of nonsmokers, people who exercise regularly, and those who take vitamin supplements, eat a balanced diet, and use certain herbs is noteworthy. Among the vaccinated subjects, 96.6%, 25.0%, 31.9%, 45.7%, and 7.8% of the IgG-positive group, versus 97.2%, 60.6%, 64.2%, 52.3%, and 6.4% of the IgG-positive non-vaccinated group, were nonsmokers, exercisers, and those taking vitamin supplements, eating a balanced diet, and using herbs, respectively. Furthermore, 93.5%, 32.3%, 35.5%, 48.4%, and 6.5% of the IgM-positive vaccinated group, versus 100.0%, 63.6%, 81.8%, 45.5%, and 4.5% of the IgM-positive non-vaccinated participants, were nonsmokers, physical exercisers, vitamin supplement users, balanced eaters, and herbalists, respectively. Persons who are free from comorbidities, young, non-obese, non-smokers, engage in physical exercise, take vitamins, eat a balanced diet, and use certain immunostimulant herbal supplements, all have a strong anti-SARS-CoV-2 humoral immune response, even if they were not vaccinated. During pandemics, vaccination of this group should not be a priority to preserve vaccine doses for high-risk vulnerable people. Even if there is a lockdown during an anticipated future epidemic or pandemic, we should prioritize healthy eating and lifestyle choices, along with increasing physical activity. |
Audience | Academic |
Author | Amer, Ibrahim Taha, Ahmed E. Sharawy, Shimaa El Ghazy, Amany A. |
AuthorAffiliation | 2 Medical Microbiology and Immunology Department, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt 3 Department of Hepatology, Gastroenterology and Infectious Diseases, Faculty of Medicine, Kafr Elsheikh University, Kafr Elsheikh 33516, Egypt; ebrahiem_amier@med.kfs.edu.eg 1 Microbiology and Immunology Unit, Department of Pathology, College of Medicine, Jouf University, Sakaka 72388, Saudi Arabia; aeattia@ju.edu.sa 4 Department of Tropical Medicine and Infectious Diseases, Faculty of Medicine, Tanta University, Tanta 31527, Egypt; shaimaa.elsharawy@med.tanta.edu.eg |
AuthorAffiliation_xml | – name: 2 Medical Microbiology and Immunology Department, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt – name: 1 Microbiology and Immunology Unit, Department of Pathology, College of Medicine, Jouf University, Sakaka 72388, Saudi Arabia; aeattia@ju.edu.sa – name: 4 Department of Tropical Medicine and Infectious Diseases, Faculty of Medicine, Tanta University, Tanta 31527, Egypt; shaimaa.elsharawy@med.tanta.edu.eg – name: 3 Department of Hepatology, Gastroenterology and Infectious Diseases, Faculty of Medicine, Kafr Elsheikh University, Kafr Elsheikh 33516, Egypt; ebrahiem_amier@med.kfs.edu.eg |
Author_xml | – sequence: 1 givenname: Ahmed E. orcidid: 0000-0002-5766-4495 surname: Taha fullname: Taha, Ahmed E. – sequence: 2 givenname: Ibrahim orcidid: 0000-0003-3778-8826 surname: Amer fullname: Amer, Ibrahim – sequence: 3 givenname: Shimaa El orcidid: 0000-0003-0308-8653 surname: Sharawy fullname: Sharawy, Shimaa El – sequence: 4 givenname: Amany A. orcidid: 0000-0002-5603-1303 surname: Ghazy fullname: Ghazy, Amany A. |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40143306$$D View this record in MEDLINE/PubMed |
BookMark | eNptks2O0zAQxyO0iP2AAy-ALHGBQ3bt2HFiLiiquruVFpAou1fLsSfBVWoXJ63Ul-CZcbalahGag8fjn_-j-bhMzpx3kCRvCb6mVOCbDSkwxbQoXyQXRAiRMkHysyP_PLns-wXGnAtcvErOGSaMUswvkt_TfrBLNVjvkG9Q5Qabzqvv83Tin9IMzdovN7P2Ds0h-FWAjerAaUDV0rsWffUufVJaW6cGMEg5g46uj85uIPR22KL5sDbghv4TqtAk-L5P56DHlKpD03a7Gqxyz9D2dfKyUV0Pb_bnVfJ4O_0xuU8fvt3NJtVDqpkQQ8oNzRUra1OLPCsZ1oCbXBScKVUDgM4YE7WmNeMmKzHNsyZvyhITXmTAQAh6lcx2usarhVyF2IKwlV5Z-RzwoZUqDFZ3IAnXLGO8NEZk0dGjbi6MKQyIHDSOWp93Wqt1vQSjY6VBdSeipy_O_pSt30hCBOMsGxU-7BWC_7WGfpBL22voOuXAr3tJSUnKDHORR_T9P-jCr0Ns5J6KtWZHVBsHJq1rfEysR1FZlbTkoxWRuv4PFc3A0uq4Yo2N8ZMP744rPZT4d50i8HEH6HHKAZoDQrAcV1UeVpX-AbYe2Nc |
Cites_doi | 10.1093/cid/ciaa344 10.3390/vaccines10091462 10.3389/fpubh.2022.825874 10.3390/vaccines10030414 10.1513/AnnalsATS.201706-447AW 10.1016/j.vaccine.2023.02.038 10.3389/fnut.2023.1152254 10.3389/fphar.2021.669362 10.1016/j.ejmech.2022.114175 10.3390/medsci12010011 10.3855/jidc.16572 10.1016/j.clinthera.2023.04.008 10.1177/20503121231158981 10.1089/met.2015.0095 10.3855/jidc.15825 10.1017/S0029665112000158 10.1016/j.talanta.2022.123409 10.3390/vaccines9091047 10.1002/jmv.27604 10.7762/cnr.2023.12.4.269 10.22207/JPAM.14.2.02 10.1001/jama.2022.0470 10.3389/fnut.2023.1161894 10.1007/978-1-0716-1884-4_2 10.1128/spectrum.01181-21 10.3390/vaccines10020292 10.1016/j.heliyon.2023.e21205 10.1016/j.maturitas.2020.08.007 10.3389/fimmu.2021.737083 10.1016/j.jtct.2022.01.019 10.1093/trstmh/tru167 10.1097/MD.0000000000029438 10.1111/bcpt.13872 10.1002/ajh.26385 10.1002/cti2.1379 10.4239/wjd.v14.i6.892 10.1186/s12916-022-02547-2 10.1128/mSphere.00019-21 10.1016/j.heliyon.2023.e20792 10.1016/j.biopha.2021.111254 10.1093/aje/kwaa191 10.3390/vaccines11010026 10.3390/ijerph19127119 10.1016/j.vaccine.2021.10.038 10.15252/emmm.202216345 10.3390/ijerph192416803 10.1038/s41385-022-00569-w 10.1016/j.puhe.2023.03.013 10.1016/j.vaccine.2021.11.051 10.3389/fendo.2022.898810 10.1016/S2213-2600(20)30239-3 10.1038/s41577-020-0359-5 10.3389/fmed.2021.778129 10.1177/00220345211020270 10.1038/s41590-021-01080-3 10.1172/JCI138759 10.3389/fimmu.2021.802858 10.3201/eid2702.201960 10.3390/ijerph20065183 10.1016/j.molimm.2023.03.007 10.7326/M21-4176 10.1007/s11481-020-09974-z 10.7717/peerj.15072 10.1001/jamainternmed.2023.0750 10.1093/ije/dyab010 10.22207/JPAM.14.4.06 10.1002/jmv.27098 10.1186/s13054-020-02952-0 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2025 MDPI AG 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2025 by the authors. 2025 |
Copyright_xml | – notice: COPYRIGHT 2025 MDPI AG – notice: 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2025 by the authors. 2025 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7U9 7X7 7XB 88E 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU COVID DWQXO FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.3390/v17030378 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection (subscription) ProQuest Central - New (Subscription) Natural Science Collection ProQuest One Community College Coronavirus Research Database ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Biological Science Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database (subscription) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals - NZ |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE CrossRef Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1999-4915 |
ExternalDocumentID | oai_doaj_org_article_16c42468dd92424cbc3b59dd7de95ec0 PMC11946420 A838686867 40143306 10_3390_v17030378 |
Genre | Journal Article |
GeographicLocations | Egypt China Saudi Arabia |
GeographicLocations_xml | – name: Egypt – name: China – name: Saudi Arabia |
GroupedDBID | --- 2WC 53G 5VS 7X7 88E 8FE 8FH 8FI 8FJ A8Z AADQD AAFWJ AAHBH AAYXX ABDBF ABUWG ACUHS AFKRA AFPKN AFZYC ALIPV ALMA_UNASSIGNED_HOLDINGS BBNVY BENPR BHPHI BPHCQ BVXVI CCPQU CITATION DIK E3Z EBD ESX FYUFA GROUPED_DOAJ GX1 HCIFZ HMCUK HYE IAO IHR ITC KQ8 LK8 M1P M48 M7P MODMG M~E O5R O5S OK1 PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RPM TR2 TUS UKHRP CGR CUY CVF ECM EIF NPM PPXIY PQGLB PMFND 3V. 7U9 7XB 8FK AZQEC COVID DWQXO GNUQQ H94 K9. PJZUB PKEHL PQEST PQUKI PRINS 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c499t-6d35a48bdb952840ce0f59764aabeeec2449bc3b46d280352f5f8801672e4e993 |
IEDL.DBID | M48 |
ISSN | 1999-4915 |
IngestDate | Wed Aug 27 01:26:15 EDT 2025 Thu Aug 21 18:39:50 EDT 2025 Fri Jul 11 18:54:20 EDT 2025 Fri Jul 25 08:45:49 EDT 2025 Tue Jun 17 21:59:30 EDT 2025 Tue Jun 10 20:53:36 EDT 2025 Sat Jul 12 02:48:53 EDT 2025 Tue Jul 01 05:30:34 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | COVID-19 SARS-CoV-2 viruses vaccines healthy immunization serological testing |
Language | English |
License | https://creativecommons.org/licenses/by/4.0 Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c499t-6d35a48bdb952840ce0f59764aabeeec2449bc3b46d280352f5f8801672e4e993 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0002-5766-4495 0000-0003-0308-8653 0000-0003-3778-8826 0000-0002-5603-1303 |
OpenAccessLink | https://www.proquest.com/docview/3181835225?pq-origsite=%requestingapplication% |
PMID | 40143306 |
PQID | 3181835225 |
PQPubID | 2032319 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_16c42468dd92424cbc3b59dd7de95ec0 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11946420 proquest_miscellaneous_3181820695 proquest_journals_3181835225 gale_infotracmisc_A838686867 gale_infotracacademiconefile_A838686867 pubmed_primary_40143306 crossref_primary_10_3390_v17030378 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2025-03-06 |
PublicationDateYYYYMMDD | 2025-03-06 |
PublicationDate_xml | – month: 03 year: 2025 text: 2025-03-06 day: 06 |
PublicationDecade | 2020 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland – name: Basel |
PublicationTitle | Viruses |
PublicationTitleAlternate | Viruses |
PublicationYear | 2025 |
Publisher | MDPI AG MDPI |
Publisher_xml | – name: MDPI AG – name: MDPI |
References | ref_50 Shields (ref_55) 2021; 100 (ref_69) 2023; 133 ref_14 ref_58 ref_57 Zohar (ref_6) 2020; 20 ref_56 ref_54 Murata (ref_60) 2021; 6 ref_53 Martino (ref_12) 2022; 97 ref_52 ref_51 Ponticelli (ref_64) 2023; 219 ref_19 ref_18 ref_17 ref_16 Fernandes (ref_3) 2023; 156 Taha (ref_2) 2020; 14 Bendavid (ref_29) 2021; 50 He (ref_32) 2023; 14 Rahmadani (ref_33) 2023; 11 ref_25 ref_24 ref_66 He (ref_63) 2022; 101 Fateh (ref_71) 2023; 12 Saeed (ref_26) 2022; 16 Bayram (ref_35) 2021; 93 Richards (ref_61) 2020; 8 Maqsood (ref_65) 2023; 11 Wang (ref_7) 2020; 130 Smits (ref_30) 2023; 41 Zhao (ref_8) 2020; 71 Bourlet (ref_22) 2022; 15 Jaber (ref_78) 2022; 295 Hetta (ref_68) 2021; 25 Shakoor (ref_72) 2021; 144 Filchakova (ref_20) 2022; 244 Taha (ref_1) 2022; 16 Renia (ref_21) 2023; 15 Mukherjee (ref_40) 2021; 16 Mohamed (ref_5) 2021; 15 Yan (ref_59) 2020; 24 Milner (ref_44) 2012; 71 Tsampasian (ref_31) 2023; 183 Accorsi (ref_47) 2022; 327 ref_77 ref_75 ref_74 ref_73 Klein (ref_39) 2015; 109 Franco (ref_23) 2021; 190 Huang (ref_11) 2022; 28 ref_37 Ruggieri (ref_41) 2016; 52 Chauss (ref_70) 2022; 23 Beninger (ref_34) 2023; 45 Khoury (ref_42) 2021; 39 Srivastava (ref_76) 2023; 9 Mishra (ref_38) 2021; 13 Padmavathi (ref_62) 2023; 9 ref_43 Taha (ref_4) 2020; 14 Meyer (ref_10) 2022; 2410 Shakiba (ref_27) 2021; 27 Dinc (ref_15) 2022; 40 Fonseca (ref_36) 2022; 94 Muschiol (ref_28) 2022; 11 ref_49 Pisoschi (ref_67) 2022; 232 Green (ref_46) 2017; 14 ref_48 ref_9 Manna (ref_45) 2015; 13 Anand (ref_13) 2022; 175 |
References_xml | – volume: 71 start-page: 2027 year: 2020 ident: ref_8 article-title: Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019 publication-title: Clin. Infect. Dis. doi: 10.1093/cid/ciaa344 – ident: ref_50 doi: 10.3390/vaccines10091462 – ident: ref_49 doi: 10.3389/fpubh.2022.825874 – ident: ref_51 – ident: ref_57 doi: 10.3390/vaccines10030414 – volume: 14 start-page: S406 year: 2017 ident: ref_46 article-title: Obesity Impairs the Adaptive Immune Response to Influenza Virus publication-title: Ann. Am. Thorac. Soc. doi: 10.1513/AnnalsATS.201706-447AW – volume: 15 start-page: 32 year: 2021 ident: ref_5 article-title: Novel coronavirus disease-related knowledge, attitudes, and practices among the residents of Al-Jouf region in Saudi Arabia publication-title: J. Infect. Dev. Ctries. – volume: 41 start-page: 2447 year: 2023 ident: ref_30 article-title: Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities publication-title: Vaccine doi: 10.1016/j.vaccine.2023.02.038 – volume: 52 start-page: 198 year: 2016 ident: ref_41 article-title: The influence of sex and gender on immunity, infection and vaccination publication-title: Ann. Ist. Super. Sanita. – ident: ref_74 doi: 10.3389/fnut.2023.1152254 – ident: ref_77 doi: 10.3389/fphar.2021.669362 – volume: 232 start-page: 114175 year: 2022 ident: ref_67 article-title: Antioxidant, anti-inflammatory and immunomodulatory roles of vitamins in COVID-19 therapy publication-title: Eur. J. Med. Chem. doi: 10.1016/j.ejmech.2022.114175 – ident: ref_73 doi: 10.3390/medsci12010011 – volume: 16 start-page: 1432 year: 2022 ident: ref_1 article-title: Role of hospital environmental surfaces in the transmission of the severe acute respiratory syndrome-Coronavirus-2 publication-title: J. Infect. Dev. Ctries. doi: 10.3855/jidc.16572 – volume: 45 start-page: 387 year: 2023 ident: ref_34 article-title: Drug-drug Interactions: An Overlooked Dimension of the COVID-19 Pandemic publication-title: Clin. Ther. doi: 10.1016/j.clinthera.2023.04.008 – volume: 11 start-page: 20503121231158981 year: 2023 ident: ref_65 article-title: Physical activities pre- and post-COVID-19 vaccination and its implementations: A narrative review publication-title: SAGE Open Med. doi: 10.1177/20503121231158981 – volume: 13 start-page: 423 year: 2015 ident: ref_45 article-title: Obesity, Oxidative Stress, Adipose Tissue Dysfunction, and the Associated Health Risks: Causes and Therapeutic Strategies publication-title: Metab. Syndr. Relat. Disord. doi: 10.1089/met.2015.0095 – volume: 295 start-page: 366 year: 2022 ident: ref_78 article-title: Clinical Trials on Alternative Medicines for COVID-19 publication-title: Stud. Health Technol. Inform. – volume: 16 start-page: 1126 year: 2022 ident: ref_26 article-title: Prevalence of SARS -CoV-2 IgG/IgM antibodies among patients in Zakho City, Kurdistan, Iraq publication-title: J. Infect. Dev. Ctries. doi: 10.3855/jidc.15825 – volume: 71 start-page: 298 year: 2012 ident: ref_44 article-title: The impact of obesity on the immune response to infection publication-title: Proc. Nutr. Soc. doi: 10.1017/S0029665112000158 – volume: 244 start-page: 123409 year: 2022 ident: ref_20 article-title: Review of COVID-19 testing and diagnostic methods publication-title: Talanta doi: 10.1016/j.talanta.2022.123409 – ident: ref_14 doi: 10.3390/vaccines9091047 – volume: 94 start-page: 2139 year: 2022 ident: ref_36 article-title: Dynamics of antibody response to CoronaVac vaccine publication-title: J. Med. Virol. doi: 10.1002/jmv.27604 – volume: 12 start-page: 269 year: 2023 ident: ref_71 article-title: The Effect of Vit-D Supplementation on the Side Effect of BioNTech, Pfizer Vaccination and Immunoglobulin G Response Against SARS-CoV-2 in the Individuals Tested Positive for COVID-19: A Randomized Control Trial publication-title: Clin. Nutr. Res. doi: 10.7762/cnr.2023.12.4.269 – ident: ref_52 – volume: 14 start-page: 1095 year: 2020 ident: ref_2 article-title: The Severe Acute Respiratory Syndrome Coronavirus-2 Pandemic: An Overview to Control Human-wildlife and Human-human Interactions publication-title: J. Pure Appl. Microbiol. doi: 10.22207/JPAM.14.2.02 – volume: 327 start-page: 639 year: 2022 ident: ref_47 article-title: Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants publication-title: JAMA doi: 10.1001/jama.2022.0470 – ident: ref_75 doi: 10.3389/fnut.2023.1161894 – volume: 2410 start-page: 27 year: 2022 ident: ref_10 article-title: Principles in Immunology for the Design and Development of Vaccines publication-title: Methods Mol. Biol. doi: 10.1007/978-1-0716-1884-4_2 – ident: ref_37 doi: 10.1128/spectrum.01181-21 – ident: ref_53 doi: 10.3390/vaccines10020292 – volume: 9 start-page: e21205 year: 2023 ident: ref_76 article-title: Promising role of Vitamin D and plant metabolites against COVID-19: Clinical trials review publication-title: Heliyon doi: 10.1016/j.heliyon.2023.e21205 – volume: 144 start-page: 108 year: 2021 ident: ref_72 article-title: Be well: A potential role for vitamin B in COVID-19 publication-title: Maturitas doi: 10.1016/j.maturitas.2020.08.007 – ident: ref_58 doi: 10.3389/fimmu.2021.737083 – volume: 28 start-page: 214.e1 year: 2022 ident: ref_11 article-title: Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation publication-title: Transplant. Cell. Ther. doi: 10.1016/j.jtct.2022.01.019 – volume: 109 start-page: 9 year: 2015 ident: ref_39 article-title: Sex-based differences in immune function and responses to vaccination publication-title: Trans. R. Soc. Trop. Med. Hyg. doi: 10.1093/trstmh/tru167 – volume: 101 start-page: e29438 year: 2022 ident: ref_63 article-title: Association between smoking and COVID-19 severity: A multicentre retrospective observational study publication-title: Medicine doi: 10.1097/MD.0000000000029438 – volume: 133 start-page: 6 year: 2023 ident: ref_69 article-title: Vitamin D and SARS-CoV-2 publication-title: Basic Clin. Pharmacol. Toxicol. doi: 10.1111/bcpt.13872 – volume: 97 start-page: 30 year: 2022 ident: ref_12 article-title: SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group publication-title: Am. J. Hematol. doi: 10.1002/ajh.26385 – volume: 11 start-page: e1379 year: 2022 ident: ref_28 article-title: Probabilistic classification of anti-SARS-CoV-2 antibody responses improves seroprevalence estimates publication-title: Clin. Transl. Immunol. doi: 10.1002/cti2.1379 – volume: 14 start-page: 892 year: 2023 ident: ref_32 article-title: Correlation between COVID-19 vaccination and diabetes mellitus: A systematic review publication-title: World J. Diabetes doi: 10.4239/wjd.v14.i6.892 – ident: ref_56 doi: 10.1186/s12916-022-02547-2 – volume: 6 start-page: e00019-21 year: 2021 ident: ref_60 article-title: Shedding of Viable Virus in Asymptomatic SARS-CoV-2 Carriers publication-title: mSphere doi: 10.1128/mSphere.00019-21 – volume: 9 start-page: e20792 year: 2023 ident: ref_62 article-title: Tobacco smoking model containing snuffing class publication-title: Heliyon doi: 10.1016/j.heliyon.2023.e20792 – volume: 25 start-page: 2131 year: 2021 ident: ref_68 article-title: The interplay between vitamin D and COVID-19: Protective or bystander? publication-title: Eur. Rev. Med. Pharmacol. Sci. – ident: ref_9 doi: 10.1016/j.biopha.2021.111254 – volume: 190 start-page: 161 year: 2021 ident: ref_23 article-title: COVID-19 in Health-Care Workers: A Living Systematic Review and Meta-Analysis of Prevalence, Risk Factors, Clinical Characteristics, and Outcomes publication-title: Am. J. Epidemiol. doi: 10.1093/aje/kwaa191 – ident: ref_24 doi: 10.3390/vaccines11010026 – ident: ref_25 doi: 10.3390/ijerph19127119 – volume: 39 start-page: 6984 year: 2021 ident: ref_42 article-title: COVID-19 vaccine—Long term immune decline and breakthrough infections publication-title: Vaccine doi: 10.1016/j.vaccine.2021.10.038 – ident: ref_18 – volume: 15 start-page: e16345 year: 2023 ident: ref_21 article-title: Acquired immunity against SARS-CoV-2 infection and vaccination publication-title: EMBO Mol. Med. doi: 10.15252/emmm.202216345 – ident: ref_54 doi: 10.3390/ijerph192416803 – volume: 15 start-page: 1170 year: 2022 ident: ref_22 article-title: Role of the humoral immune response during COVID-19: Guilty or not guilty? publication-title: Mucosal Immunol. doi: 10.1038/s41385-022-00569-w – volume: 219 start-page: 18 year: 2023 ident: ref_64 article-title: Smoking habits predict adverse effects after mRNA COVID-19 vaccine: Empirical evidence from a pilot study publication-title: Public Health doi: 10.1016/j.puhe.2023.03.013 – volume: 40 start-page: 52 year: 2022 ident: ref_15 article-title: Inactive SARS-CoV-2 vaccine generates high antibody responses in healthcare workers with and without prior infection publication-title: Vaccine doi: 10.1016/j.vaccine.2021.11.051 – ident: ref_48 doi: 10.3389/fendo.2022.898810 – volume: 8 start-page: 664 year: 2020 ident: ref_61 article-title: Tobacco smoking and COVID-19 infection publication-title: Lancet Respir. Med. doi: 10.1016/S2213-2600(20)30239-3 – volume: 20 start-page: 392 year: 2020 ident: ref_6 article-title: Dissecting antibody-mediated protection against SARS-CoV-2 publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-020-0359-5 – ident: ref_17 doi: 10.3389/fmed.2021.778129 – volume: 100 start-page: 1220 year: 2021 ident: ref_55 article-title: COVID-19: Seroprevalence and Vaccine Responses in UK Dental Care Professionals publication-title: J. Dent. Res. doi: 10.1177/00220345211020270 – volume: 23 start-page: 62 year: 2022 ident: ref_70 article-title: Autocrine vitamin D signaling switches off pro-inflammatory programs of TH1 cells publication-title: Nat. Immunol. doi: 10.1038/s41590-021-01080-3 – volume: 130 start-page: 5235 year: 2020 ident: ref_7 article-title: Kinetics of viral load and antibody response in relation to COVID-19 severity publication-title: J. Clin. Investig. doi: 10.1172/JCI138759 – ident: ref_16 doi: 10.3389/fimmu.2021.802858 – volume: 27 start-page: 636 year: 2021 ident: ref_27 article-title: Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020 publication-title: Emerg. Infect. Dis. doi: 10.3201/eid2702.201960 – ident: ref_66 doi: 10.3390/ijerph20065183 – volume: 156 start-page: 148 year: 2023 ident: ref_3 article-title: Influence of age, gender, previous SARS-CoV-2 infection, and pre-existing diseases in antibody response after COVID-19 vaccination: A review publication-title: Mol. Immunol. doi: 10.1016/j.molimm.2023.03.007 – volume: 175 start-page: 371 year: 2022 ident: ref_13 article-title: SARS-CoV-2 Vaccine Antibody Response and Breakthrough Infection in Patients Receiving Dialysis publication-title: Ann. Intern. Med. doi: 10.7326/M21-4176 – volume: 16 start-page: 38 year: 2021 ident: ref_40 article-title: Is COVID-19 Gender-sensitive? publication-title: J. Neuroimmune Pharmacol. doi: 10.1007/s11481-020-09974-z – volume: 11 start-page: e15072 year: 2023 ident: ref_33 article-title: Potential drug-drug interactions and their associated factors in hospitalized COVID-19 patients with comorbidities publication-title: PeerJ doi: 10.7717/peerj.15072 – volume: 183 start-page: 566 year: 2023 ident: ref_31 article-title: Risk Factors Associated With Post-COVID-19 Condition: A Systematic Review and Meta-analysis publication-title: JAMA Intern. Med. doi: 10.1001/jamainternmed.2023.0750 – volume: 13 start-page: e19879 year: 2021 ident: ref_38 article-title: Waning of Anti-spike Antibodies in AZD1222 (ChAdOx1) Vaccinated Healthcare Providers: A Prospective Longitudinal Study publication-title: Cureus – volume: 50 start-page: 410 year: 2021 ident: ref_29 article-title: COVID-19 antibody seroprevalence in Santa Clara County, California publication-title: Int. J. Epidemiol. doi: 10.1093/ije/dyab010 – ident: ref_19 – ident: ref_43 – volume: 14 start-page: 2287 year: 2020 ident: ref_4 article-title: Can COVID-19 Be Transmitted Sexually by Semen? publication-title: J. Pure Appl. Microbiol. doi: 10.22207/JPAM.14.4.06 – volume: 93 start-page: 5560 year: 2021 ident: ref_35 article-title: Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers publication-title: J. Med. Virol. doi: 10.1002/jmv.27098 – volume: 24 start-page: 245 year: 2020 ident: ref_59 article-title: Duration of SARS-CoV-2 viral RNA in asymptomatic carriers publication-title: Crit. Care doi: 10.1186/s13054-020-02952-0 |
SSID | ssj0066907 |
Score | 2.378424 |
Snippet | It is essential to comprehend the humoral immune response to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its vaccines to maximize the... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 378 |
SubjectTerms | Adaptive immunity Adolescent Adult Antibodies Antibodies, Viral - blood Anticoagulants Asymptomatic B cells College students Comorbidity Coronaviruses COVID-19 COVID-19 - epidemiology COVID-19 - immunology COVID-19 - prevention & control COVID-19 vaccines COVID-19 Vaccines - administration & dosage COVID-19 Vaccines - immunology Cross-Sectional Studies Dietary supplements Disease transmission Egypt - epidemiology Enzyme-linked immunosorbent assay Enzymes Ethylenediaminetetraacetic acid Female Health aspects healthy Herbs Humans Immune response Immune response (humoral) Immunity (Disease) immunization Immunoassay Immunoglobulin G Immunoglobulin G - blood Immunoglobulin M Immunoglobulin M - blood Immunoglobulins Immunology Immunostimulants Infections Lymphocytes Male Microbiota Pandemics Physical activity Physiological aspects Sample size SARS-CoV-2 SARS-CoV-2 - immunology Seroepidemiologic Studies serological testing Serology Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Statistical analysis Students Students - statistics & numerical data Universities Vaccination Vaccination - statistics & numerical data Vaccines Viruses Vitamins Young Adult |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals - NZ dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQJSQuCMor0FYGIXGydpPYTsItrLa0SO2BpVVvkT12yl4SRLdI_RP8Zmbs7DYRBy4op8QTyZ6HZ0aamY-x91UBGBc7EKCNFVKCErYCEEZb07rCtm3ocj071ycX8suVuhpBfVFNWBwPHBk3SzXITOrSuYo6GcBCblXlXOF8pTyEbB193jaZinewppwvzhHKMamf_UpJsXPCUht5nzCk_--reOSLpnWSI8dz_IQ9HiJGXsedPmUPfLfPHkYMybtn7PcSjTT2H_K-5XW3WYtV_XUlFv2lyPjp9dns9PozxzuB8E5Qr8iUeU0YQ_y878SlAVh3GHE6bjrHR6_3NRt8FSdg3nzkNV_QycQqlHDRxpYEZIZKFojunrOL4-W3xYkYQBYEYLKzEdrlysjSOlspdFVz8PMWkwwtjbHee0D3XxHPpXYEZKWyVrVo86kuMi89Rjcv2F7Xd_4V4wqFlIH0MvSnAliDckNfYCyKHD8k7N2W-c2POEujwRyEJNTsJJSwTySWHQGNvw4fUCmaQSmafylFwj6QUBsyUpQcmKHXAPdJ466ausxLTU-RsIMJJRoXTJe3atEMxn3T4DWYhsBVJeztbpn-pIK1zve3A0021xXSvIxatDuSpJmKmKolrJzo1-TM05Vu_T2M_k7TSmLGOH_9P7j0hj3KCM044EkesL3Nz1t_iCHWxh4Fa_oDNIcnGQ priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fb9MwELZgCIkXxG8CAxmExJPVNLGdhBcUqo4NaXugbOpbZJ-d0pdkrB3S_gn-Zu6cNGuEhPqU-FLZve_su_TuPsY-FBmgX-xAgDZWSAlK2AJAGG1N7TJb16HK9fRMH5_Lb0u17F-4bfq0yt2eGDZq1wK9I58g9qbBW1CfL38JYo2if1d7Co277B61LiNUZ8sh4NIU-XXdhFIM7Se_pwTvlBjV9s6g0Kr_3w1570QaZ0vuHT9Hj9jD3m_kZafox-yOb56w-x2T5M1T9meOptpVIfK25mWzXYtF-X0hZu2FSPjJ6nRysvrKcWcg1hNEFxk0L4lpiJ-1jbgwAOsG_U7HTeP43uVt5gZfdH0wN594yWe0MrEIiVw0sTnRmSHUgtDNM3Z-NP8xOxY91YIADHm2QrtUGZlbZwuFB1YMPq4x1NDSGOu9B3QCCgupldoRnZVKalWj5U91lnjp0cd5zg6atvEvGVe5cwlIL0OVKoA1Uud4IhiLiscbEXu_-_Gry66jRoWRCGmoGjQUsS-klkGAmmCHG-3VquptqppqkAl-uXMFFbkATVAVzmXOF8pDHLGPpNSKTBU1B6avOMB5UtOrqszTXNMni9jhSBJNDMbDO1hUvYlvqltARuzdMExPUtpa49vrXiaJdYEyLzoUDUuS1FkRA7aI5SN8jdY8HmnWP0MDcMS6xLgxfvX_eb1mDxJiKw58kYfsYHt17d-gC7W1b4Od_AVEDR4R priority: 102 providerName: ProQuest |
Title | Estimation of Anti-SARS-CoV-2 IgM/IgG Seroprevalence Among Non-Vaccinated and Vaccinated University Students: A Cross-Sectional Egyptian Study |
URI | https://www.ncbi.nlm.nih.gov/pubmed/40143306 https://www.proquest.com/docview/3181835225 https://www.proquest.com/docview/3181820695 https://pubmed.ncbi.nlm.nih.gov/PMC11946420 https://doaj.org/article/16c42468dd92424cbc3b59dd7de95ec0 |
Volume | 17 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3ri9NAEF_ugeAX8X3Rs6wi-Gm9Jt3dJIJIrvQeQotc7dFvYV-pBUm01xP7T_g3O7NJY4N-kEAgu5Owm5nZmUl25kfI6zQ24Bdbw4xUmnFuBNOpMUxJrQob66LwWa7jibyY8Y9zMd8jW4zN5gXe_DO0Qzyp2err25_fNx9A4d9jxAkh-8mPEMV2ECf75BAMUoxABmPe_kyQGAD6n8spAqqFoi4w1L21Y5Z89f6_1-gdI9XdQLljkc7uk3uNK0mzmvcPyJ4rH5I7Nbjk5hH5NQLtrRMTaVXQrFwv2TS7mrJhdc0ierkYn1wuziksFgiEAgKHOk4zBB-ik6pk18qYZQmuqKWqtHTn8s9mDjqtS2PevKMZHeLM2NTv7cKBjRDhDKTPE20ek9nZ6PPwgjXoC8xAFLRm0g6E4om2OhVgw_rG9QuIPiRXSjvnDPgFqTYDzaVFhCsRFaKAxSCUceS4A7fnCTkoq9IdESoSayPDHfeJq8ZoxWUCRkJpkAVoCMir7cvPv9VFNnIITpBDecuhgJwiW1oCrIvtG6rVIm_ULA-l4RE83NoU814MDlCk1sbWpcKZfkDeIFNzlCfgnFFNEgKME-tg5VkySCQecUCOO5SgdabbvRWLfCu0OayPofdoRUBett14J-5kK11129BEfZkCzdNaitopcSy2CDFcQJKOfHXm3O0pl198TfAwTDmEkv1n_z3B5-RuhFjGHk3ymBysV7fuBThYa90j-_E87pHD09Hk01XPf6aA8_k87HnF-g0THioJ |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF5VRQguiDeGAgsCcVrVj_Xai4SQCSkJbXIgbZWb63045GKXJgXlT_BT-I3MrJ00FhK3Kid7x9Fu5u3MzEfIG5loiIuNZloUinGuY6ak1qwQqihNosrSdbmOxmJwwr9O4-kO-bPuhcGyyrVNdIba1Brfke-D7AUuWog_nv9giBqF_66uITQasTi0q1-Qsi0-DD8Df9-G4UH_uDdgLaoA0xDdL5kwUVzwVBklY7DNvrZ-CVG14EWhrLUa_J1UOlJcGERuisMyLkHIA5GElluJw5fA5N8Ax-tjspdMNwmewEyzmV4URdLf_xmgOkWI4Lbl8xw0wL8OYMsDdqszt9zdwV1yp41TadYI1j2yY6v75GaDXLl6QH73wTQ0XY-0LmlWLedskn2bsF59ykI6nI32h7MvFCwRoqyANKMBoRkiG9FxXbHTQut5BXGuoUVl6NblVaUInTRzNxfvaUZ7eDI2cYVjuLE-wqeBaDui1UNyci1MeER2q7qyTwiNU2NCzS13XbFaq4KLFDxQoUDQ4IZHXq9__Py8meCRQ-aDHMo3HPLIJ2TLhgCHbrsb9cUsb3U4D4TmIXy5MRKbajRuMJbGJMbK2GrfI--QqTmaBuCcLtoOB9gnDtnKszRKBX4Sj-x1KEGldXd5LRZ5a1IW-ZUCeOTVZhmfxDK5ytaXLU3oCwk0jxsp2hyJ4yRHSBA9knbkq3Pm7ko1_-4GjgeB5JCn-k__v6-X5NbgeHSUHw3Hh8_I7RCRkh1W5R7ZXV5c2ucQvi3VC6czlJxdt5L-BfSbWoY |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF5VqUBcEG8MBRYE4rSKH-u1FwkhN01oKI2qhla9ud6HQy52aVJQ_gQ_iF_HjB9pLCRuVU72jqPdzNuZmY-QtzLSEBcbzbTIFONch0xJrVkmVJabSOV51eV6OBH7J_zLWXi2Rf60vTBYVtnaxMpQm1LjO_I-yJ5XRQthP2_KIo72Rp8ufjBEkMJ_Wls4jVpEDuzqF6Rvi4_jPeD1O98fDb8N9lmDMMA0RPpLJkwQZjxWRskQ7LSrrZtDhC14lilrrQbfJ5UOFBcGUZxCPw9zEHhPRL7lVuIgJjD_2xFmRT2yvTucHB23fkBg3lnPMgoC6fZ_eqhcAeK5bXjACijgX3ew4Q-7tZobzm90j9xtolaa1GJ2n2zZ4gG5VeNYrh6S30MwFHUPJC1zmhTLOZsmx1M2KE-ZT8ezw_549pmCXULMFZBtNCc0QZwjOikLdpppPS8g6jU0KwzduLyuG6HTegrn4gNN6ABPxqZVGRlubIhgaiDoFdHqETm5ETY8Jr2iLOxTQsPYGF9zy6seWa1VxkUM_ihTIHZwwyFv2h8_vajneaSQByGH0jWHHLKLbFkT4Aju6kZ5OUsbjU49obkPX26MxBYbjRsMpTGRsTK02nXIe2RqioYCOKezpt8B9okjt9IkDmKBn8ghOx1KUHDdXW7FIm0MzCK9VgeHvF4v45NYNFfY8qqh8V0hgeZJLUXrI3Gc6wjpokPijnx1ztxdKebfq_Hjnic5ZK3us__v6xW5DQqafh1PDp6TOz7CJlfAlTukt7y8si8glluql43SUHJ-03r6F-U4YCE |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Estimation+of+Anti-SARS-CoV-2+IgM%2FIgG+Seroprevalence+Among+Non-Vaccinated+and+Vaccinated+University+Students%3A+A+Cross-Sectional+Egyptian+Study&rft.jtitle=Viruses&rft.au=Taha%2C+Ahmed+E&rft.au=Amer%2C+Ibrahim&rft.au=Sharawy%2C+Shimaa+El&rft.au=Ghazy%2C+Amany+A&rft.date=2025-03-06&rft.pub=MDPI+AG&rft.issn=1999-4915&rft.eissn=1999-4915&rft.volume=17&rft.issue=3&rft_id=info:doi/10.3390%2Fv17030378&rft.externalDocID=A838686867 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1999-4915&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1999-4915&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1999-4915&client=summon |